Early Insight Into Kidney Injury

AKI is common, costly and often detected too late.

Acute kidney injury is a common and life-threatening condition in hospital and intensive care settings. Current literature reports that AKI may affect approximately 20% of general ward patients and up to 50% of ICU patients. In patients requiring renal replacement therapy, mortality can exceed 50%.

Despite this burden, AKI may remain under-recognized in real-world hospital care. A 2025 systematic review of AKI clinical practice guidelines reported that 68% of in-hospital AKI cases remained undiagnosed, correlating with 21.1% mortality, compared with 3.8% mortality in non-AKI patients.

Clinical & analytical performance

From urinary trehalase biology to measurable kidney injury insight.

Argeron NephroTesT® is designed to convert urinary trehalase activity into a practical laboratory result that can support biomarker-based evaluation of proximal tubular stress. The platform is developed to work with standard urine glucose testing infrastructure and to provide a scalable workflow for clinical laboratories, hospitals and research centers.

Clinical & research application areas

Argeron NephroTesT® is positioned as a urinary trehalase activity platform for biomarker-based insight into proximal tubular stress across multiple clinical and research settings.

A global health and economic challenge

Kidney disease creates a substantial clinical and economic burden worldwide. CKD is estimated to affect approximately 700–840 million people, with worldwide prevalence estimated at 8–14%. Costs increase sharply as disease progresses toward kidney failure and kidney replacement therapy.

A global review across 31 countries and regions reported mean annual per-patient costs of approximately $3,060 for CKD stage G3a, $57,334 for hemodialysis, $49,490 for peritoneal dialysis and $75,326 for the first year after kidney transplant. The same study estimated mean annual costs of $5,975 for AKI-related complications.